Min Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Min Zhao has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Guixian Chen
The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China
6 shared publicationsHuiying Ouyang
The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China
6 shared publicationsYibo Zhan
The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China
6 shared publications- Yuanqi Zhao
The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, China
6 shared publications Haoyou Xu
The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China
5 shared publicationsXiaojun Li
Zhongshan Hospital of Traditional Chinese Medicine Affiliated to Guangzhou University of Traditional Chinese Medicine, Zhongshan, China
5 shared publications
Latest Publications
- Open Access
- 9 October 2026
- Published by Springer Nature in BMC Cardiovascular Disorders
PD-1 inhibitor-associated myasthenia gravis with acute myocardial injury: a case report
Background: PD-1 inhibitors can cause serious immune-related adverse events, including myasthenia gravis (MG). The occurrence of myocardial injury during immune checkpoint inhibitor therapy can pose diagnostic challenges. Case presentation: A 65-year-old man with hepatocellular carcinoma developed severe PD-1 inhibitor-associated MG after receiving tislelizumab. During the acute phase, he developed acute myocardial injury, with marked hs-cTnT elevation and new ST-segment depression on electrocardiography, and non-ST-segment elevation myocardial infarction (NSTEMI) was clinically suspected. His myasthenic symptoms gradually improved with immunosuppressive therapy, whereas hs-cTnT remained elevated during follow-up. Seven months after the initial presentation, he developed an ST-segment elevation myocardial infarction due to total occlusion of the proximal left anterior descending artery and underwent percutaneous coronary intervention. Conclusion: This case highlights the need to carefully evaluate the underlying cause of myocardial injury in patients with severe PD-1 inhibitor-associated MG. Persistent hs-cTnT may identify patients at increased cardiovascular risk, although the prognostic significance of this finding requires further investigation.
- 9 October 2026
- Published by Springer Nature in BMC Cardiovascular Disorders
Open AccessPD-1 inhibitor-associated myasthenia gravis with acute myocardial injury: a case report
Background: PD-1 inhibitors can cause serious immune-related adverse events, including myasthenia gravis (MG). The occurrence of myocardial injury during immune checkpoint inhibitor therapy can pose diagnostic challenges. Case presentation: A 65-year-old man with hepatocellular carcinoma developed severe PD-1 inhibitor-associated MG after receiving tislelizumab. During the acute phase, he developed acute myocardial injury, with marked hs-cTnT elevation and new ST-segment depression on electrocardiography, and non-ST-segment elevation myocardial infarction (NSTEMI) was clinically suspected. His myasthenic symptoms gradually improved with immunosuppressive therapy, whereas hs-cTnT remained elevated during follow-up. Seven months after the initial presentation, he developed an ST-segment elevation myocardial infarction due to total occlusion of the proximal left anterior descending artery and underwent percutaneous coronary intervention. Conclusion: This case highlights the need to carefully evaluate the underlying cause of myocardial injury in patients with severe PD-1 inhibitor-associated MG. Persistent hs-cTnT may identify patients at increased cardiovascular risk, although the prognostic significance of this finding requires further investigation.
- Open Access
- 21 September 2026
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 17, 1872558
Early eGFR fluctuation and 180-day outcome after thrombectomy for large-artery atherosclerotic stroke
Background: To investigate whether early estimated glomerular filtration rate (eGFR) fluctuation is associated with 180-day functional outcome in patients with large-artery atherosclerotic stroke undergoing endovascular thrombectomy. Methods: We conducted a multicenter retrospective cohort study of consecutive patients with acute ischemic stroke attributed to large-artery atherosclerosis who underwent endovascular thrombectomy between January 1, 2024 and December 31, 2024. Among 108 patients with 180-day follow-up, 93 had at least two actual eGFR measurements within the first 7 days and comprised the primary complete-case cohort; the full 108-patient cohort after multiple imputation was examined in a sensitivity analysis. Early eGFR fluctuation was defined as the absolute difference between the maximum and minimum eGFR values within 7 days after admission. Poor functional outcome was defined as a modified Rankin Scale score of 3–6 at 180 days. Results: In the primary cohort of 93 patients, 54 had poor functional outcomes. Greater early eGFR fluctuation was associated with poor 180-day functional outcome (adjusted OR per 1 mL/min/1.73 m2 increase, 1.078; 95% CI, 1.019–1.139; p = 0.008). The association was consistent in Firth penalized regression (OR, 1.068; 95% CI, 1.020–1.134; p = 0.002) and bootstrap internal validation. It remained significant after adjustment for the number of eGFR measurements (adjusted OR, 1.065; 95% CI, 1.006–1.127; p = 0.029) and in the 108-patient post-imputation sensitivity cohort (adjusted OR, 1.089; 95% CI, 1.030–1.151; p = 0.003). Restricted cubic spline analysis showed an overall association ( p = 0.012) without evidence of nonlinearity ( p = 0.471). Conclusion: Greater early eGFR fluctuation was associated with poor 180-day functional outcome after thrombectomy in patients with large-artery atherosclerotic stroke. Early eGFR fluctuation may represent an exploratory prognostic marker that requires prospective external validation.
- 21 September 2026
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 17, 1872558
Open AccessEarly eGFR fluctuation and 180-day outcome after thrombectomy for large-artery atherosclerotic stroke
Background: To investigate whether early estimated glomerular filtration rate (eGFR) fluctuation is associated with 180-day functional outcome in patients with large-artery atherosclerotic stroke undergoing endovascular thrombectomy. Methods: We conducted a multicenter retrospective cohort study of consecutive patients with acute ischemic stroke attributed to large-artery atherosclerosis who underwent endovascular thrombectomy between January 1, 2024 and December 31, 2024. Among 108 patients with 180-day follow-up, 93 had at least two actual eGFR measurements within the first 7 days and comprised the primary complete-case cohort; the full 108-patient cohort after multiple imputation was examined in a sensitivity analysis. Early eGFR fluctuation was defined as the absolute difference between the maximum and minimum eGFR values within 7 days after admission. Poor functional outcome was defined as a modified Rankin Scale score of 3–6 at 180 days. Results: In the primary cohort of 93 patients, 54 had poor functional outcomes. Greater early eGFR fluctuation was associated with poor 180-day functional outcome (adjusted OR per 1 mL/min/1.73 m2 increase, 1.078; 95% CI, 1.019–1.139; p = 0.008). The association was consistent in Firth penalized regression (OR, 1.068; 95% CI, 1.020–1.134; p = 0.002) and bootstrap internal validation. It remained significant after adjustment for the number of eGFR measurements (adjusted OR, 1.065; 95% CI, 1.006–1.127; p = 0.029) and in the 108-patient post-imputation sensitivity cohort (adjusted OR, 1.089; 95% CI, 1.030–1.151; p = 0.003). Restricted cubic spline analysis showed an overall association ( p = 0.012) without evidence of nonlinearity ( p = 0.471). Conclusion: Greater early eGFR fluctuation was associated with poor 180-day functional outcome after thrombectomy in patients with large-artery atherosclerotic stroke. Early eGFR fluctuation may represent an exploratory prognostic marker that requires prospective external validation.
- Open Access
- 24 January 2026
- Published by Elsevier in Phytomedicine
- Vol. 153, 157887
Xing-nao-sheng-jiang powder alleviates ischemic stroke in rats by inhibiting pyroptosis-related microglial ETosis: An emerging perspective on microglial ETosis
- 24 January 2026
- Published by Elsevier in Phytomedicine
- Vol. 153, 157887
Open AccessXing-nao-sheng-jiang powder alleviates ischemic stroke in rats by inhibiting pyroptosis-related microglial ETosis: An emerging perspective on microglial ETosis
- Open Access
- 1 August 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1585126
Adefovir dipivoxil-associated Fanconi syndrome combined with peripheral neuropathy: a case report and literature review
Long-term use of low-dose adefovir dipivoxil (ADV) has been increasingly associated with Fanconi syndrome; however, cases of Fanconi syndrome combined with peripheral neuropathy remain rare. Here, we report a 67-year-old man who developed progressive limb weakness and sensory abnormalities after approximately 6 years of treatment with 10 mg ADV. He was diagnosed with ADV-associated Fanconi syndrome accompanied by peripheral neuropathy. Following the substitution of ADV with entecavir and 5 months to 6 months of phosphate supplementation, the patient’s muscle weakness nearly resolved, and peripheral nerve damage showed significant improvement.
- 1 August 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1585126
Open AccessAdefovir dipivoxil-associated Fanconi syndrome combined with peripheral neuropathy: a case report and literature review
Long-term use of low-dose adefovir dipivoxil (ADV) has been increasingly associated with Fanconi syndrome; however, cases of Fanconi syndrome combined with peripheral neuropathy remain rare. Here, we report a 67-year-old man who developed progressive limb weakness and sensory abnormalities after approximately 6 years of treatment with 10 mg ADV. He was diagnosed with ADV-associated Fanconi syndrome accompanied by peripheral neuropathy. Following the substitution of ADV with entecavir and 5 months to 6 months of phosphate supplementation, the patient’s muscle weakness nearly resolved, and peripheral nerve damage showed significant improvement.
- Open Access
- 4 June 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1533905
Early statin use might reduce the hemorrhagic transformation among acute ischemic stroke patients with recanalization therapy: a retrospective cohort study
Objective: To evaluate the relationship between early statin administration and hemorrhagic transformation (HT) in patients with acute ischemic stroke (AIS) patients following recanalization therapy.Methods: This retrospective study included AIS patients who underwent recanalization therapy (intravenous thrombolysis, endovascular treatment, or a combination of both) and categorized them into two groups based on whether statins were administered within 24 h of recanalization therapy. The primary outcome was the occurrence of HT during hospitalization. Secondary outcomes included in-hospital mortality, favorable clinical outcomes (mRS 0–2) at discharge, and neurological improvement 7 ± 2 days post-stroke (defined as a reduction of ≥4 points in NIHSS from baseline).Results: A total of 266 AIS patients were analyzed, with 164 (61.7%) receiving statins within 24 h (24 h-statins group). The 24 h-statins group demonstrated a significantly lower risk of HT compared to the non-24 h-statins group (4.9% vs. 21.6%, p < 0.001). In-hospital mortality was also lower in the 24 h-statins group, although not statistically significant (4.9% vs. 10.8%, p = 0.076). Favorable clinical outcomes were more frequent in the 24 h-statins group than in the non-24 h-statins group (60.5% vs. 36.7%, p < 0.001). Furthermore, a greater proportion of patients in the 24 h-statins group showed neurological improvement (51.8% vs. 35.1%, p = 0.019). Adjusted multivariate analysis revealed that early statin use was independently associated with a reduced risk of HT (OR 0.16, 95% CI 0.06–0.49, p < 0.001), as well as a positive association with favorable clinical outcomes (OR 3.63, 95% CI 1.42–9.28, p = 0.007) and neurological improvement (OR 5.23, 95% CI 1.96–13.91, p < 0.001). Subgroup analysis indicated that among patients with elevated low-density lipoprotein (LDL) levels, early statin therapy was linked to a lower risk of HT (P for interaction = 0.018).Conclusion: Early statin administration within 24 h of recanalization therapy, in AIS patients was associated with reduced risk of HT and improved neurological outcomes. For patients with elevated LDL levels, early statin therapy may further decrease the risk of HT.
- 4 June 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1533905
Open AccessEarly statin use might reduce the hemorrhagic transformation among acute ischemic stroke patients with recanalization therapy: a retrospective cohort study
Objective: To evaluate the relationship between early statin administration and hemorrhagic transformation (HT) in patients with acute ischemic stroke (AIS) patients following recanalization therapy.Methods: This retrospective study included AIS patients who underwent recanalization therapy (intravenous thrombolysis, endovascular treatment, or a combination of both) and categorized them into two groups based on whether statins were administered within 24 h of recanalization therapy. The primary outcome was the occurrence of HT during hospitalization. Secondary outcomes included in-hospital mortality, favorable clinical outcomes (mRS 0–2) at discharge, and neurological improvement 7 ± 2 days post-stroke (defined as a reduction of ≥4 points in NIHSS from baseline).Results: A total of 266 AIS patients were analyzed, with 164 (61.7%) receiving statins within 24 h (24 h-statins group). The 24 h-statins group demonstrated a significantly lower risk of HT compared to the non-24 h-statins group (4.9% vs. 21.6%, p < 0.001). In-hospital mortality was also lower in the 24 h-statins group, although not statistically significant (4.9% vs. 10.8%, p = 0.076). Favorable clinical outcomes were more frequent in the 24 h-statins group than in the non-24 h-statins group (60.5% vs. 36.7%, p < 0.001). Furthermore, a greater proportion of patients in the 24 h-statins group showed neurological improvement (51.8% vs. 35.1%, p = 0.019). Adjusted multivariate analysis revealed that early statin use was independently associated with a reduced risk of HT (OR 0.16, 95% CI 0.06–0.49, p < 0.001), as well as a positive association with favorable clinical outcomes (OR 3.63, 95% CI 1.42–9.28, p = 0.007) and neurological improvement (OR 5.23, 95% CI 1.96–13.91, p < 0.001). Subgroup analysis indicated that among patients with elevated low-density lipoprotein (LDL) levels, early statin therapy was linked to a lower risk of HT (P for interaction = 0.018).Conclusion: Early statin administration within 24 h of recanalization therapy, in AIS patients was associated with reduced risk of HT and improved neurological outcomes. For patients with elevated LDL levels, early statin therapy may further decrease the risk of HT.
- Open Access
- 26 April 2025
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 34 (7) , 108314
Shengjiang powder ameliorates cell pyroptosis and inflammation induced by MCAO in rats through the NLRP3/Caspase-1 pathway
- 26 April 2025
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 34 (7) , 108314
Open AccessShengjiang powder ameliorates cell pyroptosis and inflammation induced by MCAO in rats through the NLRP3/Caspase-1 pathway
- Open Access
- 29 January 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1309583
Risk factors of neuropathic pain in multiple sclerosis: a retrospective case-cohort study
Background: Pain is a common symptom in multiple sclerosis (MS), especially neuropathic pain, which has a significant impact on patients’ mental and physical health and quality of life. However, risk factors that related to neuropathic pain, still remain unclear.Objective: The study aimed to explore the risk factors of neuropathic pain among MS patients.Materials and methods: This retrospective study examined the consecutive patients diagnosed with MS in the Department of Neurology of Guangdong Provincial Hospital of Chinese Medicine between August 2011 and October 2022. Neuropathic pain was defined as “pain arising as a direct consequence of a lesion or disease affecting the somatosensory system”. Demographic and clinical features were obtained from the electronic system of the hospital.Results: Our cohort revealed that the prevalence of patients with neuropathic pain in MS was 34.1%. The results indicated that the longer the spinal lesions, the greater the neuropathic pain risks (2-4: OR, 13.3(2.1-82), >5: OR, 15.2(2.7-86.8), p for tread: 0.037). Meanwhile, multivariate regression analysis showed that cervical and thoracic lesions (OR 4.276, 95% CI 1.366-13.382, P = 0.013), upper thoracic lesions (T1-T6) (OR 3.047, 95% CI 1.018-9.124, P = 0.046) were positively correlated with neuropathic pain, while basal ganglia lesions (OR 0.188, 95% CI 0.044-0.809, P = 0.025) were negatively correlated with neuropathic pain among MS patients.Conclusion: Extended spinal lesions (≥3 spinal lesions), cervical and thoracic lesions, upper thoracic lesions were independent risk factors of neuropathic pain among MS patients. Furthermore, our study found that the longer the spinal lesions, the greater the neuropathic pain risks.
- 29 January 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1309583
Open AccessRisk factors of neuropathic pain in multiple sclerosis: a retrospective case-cohort study
Background: Pain is a common symptom in multiple sclerosis (MS), especially neuropathic pain, which has a significant impact on patients’ mental and physical health and quality of life. However, risk factors that related to neuropathic pain, still remain unclear.Objective: The study aimed to explore the risk factors of neuropathic pain among MS patients.Materials and methods: This retrospective study examined the consecutive patients diagnosed with MS in the Department of Neurology of Guangdong Provincial Hospital of Chinese Medicine between August 2011 and October 2022. Neuropathic pain was defined as “pain arising as a direct consequence of a lesion or disease affecting the somatosensory system”. Demographic and clinical features were obtained from the electronic system of the hospital.Results: Our cohort revealed that the prevalence of patients with neuropathic pain in MS was 34.1%. The results indicated that the longer the spinal lesions, the greater the neuropathic pain risks (2-4: OR, 13.3(2.1-82), >5: OR, 15.2(2.7-86.8), p for tread: 0.037). Meanwhile, multivariate regression analysis showed that cervical and thoracic lesions (OR 4.276, 95% CI 1.366-13.382, P = 0.013), upper thoracic lesions (T1-T6) (OR 3.047, 95% CI 1.018-9.124, P = 0.046) were positively correlated with neuropathic pain, while basal ganglia lesions (OR 0.188, 95% CI 0.044-0.809, P = 0.025) were negatively correlated with neuropathic pain among MS patients.Conclusion: Extended spinal lesions (≥3 spinal lesions), cervical and thoracic lesions, upper thoracic lesions were independent risk factors of neuropathic pain among MS patients. Furthermore, our study found that the longer the spinal lesions, the greater the neuropathic pain risks.
- Open Access
- 4 January 2024
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 13, 1257317
Gut microbiota as predictors of the occurrence of high on-treatment platelet reactivity in acute ischemic stroke patients
Introduction: In this study, we aimed to investigate the association between gut microbiota and high on-treatment platelet reactivity (HTPR) in patients with acute ischemic stroke (AIS).Methods: We enrolled a total of 48 AIS patients, including 19 HTPR patients and 29 non-high on-treatment platelet reactivity (NHTPR) patients, along with 10 healthy controls. Clinical and laboratory data, as well as stool samples, were collected from all participants. The composition and function of gut microbiota were assessed using 16S rRNA sequencing. Differences in the gut microbiota between the two groups were analyzed, and a diagnostic model based on the gut microbiota was established using random forest model.Results: HTPR patients exhibited a decreased microbial richness compared to NHTPR patients. Additionally, the relative abundance of unidentified_Clostridia and Ralstonia was lower in HTPR patients. Significant differences in biological functions, such as toxoplasmosis, were observed between the two groups. The combination of Ralstonia, unidentified-Clostridia, Mailhella, Anaerofustis, and Aggregatibacter showed excellent predictive ability for HTPR occurrence (AUC=0.896). When comparing AIS patients with healthy controls, alterations in the microbiota structure were observed in AIS patients, with imbalances in short-chain fatty acid-producing bacteria and pathogenic bacteria. Significant differences in biological functions, such as oxidative phosphorylation, were noted between the two groups. The combination of Alloprevotella, Terrisporobacter, Streptococcus, Proteus, and unidentified_Bacteria exhibited strong predictive power for AIS occurrence (AUC=0.994).Conclusions: This study is the first to uncover the microbial characteristics of HTPR in AIS patients and demonstrate the predictive potential of specific bacterial combinations for HTPR occurrence.
- 4 January 2024
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 13, 1257317
Open AccessGut microbiota as predictors of the occurrence of high on-treatment platelet reactivity in acute ischemic stroke patients
Introduction: In this study, we aimed to investigate the association between gut microbiota and high on-treatment platelet reactivity (HTPR) in patients with acute ischemic stroke (AIS).Methods: We enrolled a total of 48 AIS patients, including 19 HTPR patients and 29 non-high on-treatment platelet reactivity (NHTPR) patients, along with 10 healthy controls. Clinical and laboratory data, as well as stool samples, were collected from all participants. The composition and function of gut microbiota were assessed using 16S rRNA sequencing. Differences in the gut microbiota between the two groups were analyzed, and a diagnostic model based on the gut microbiota was established using random forest model.Results: HTPR patients exhibited a decreased microbial richness compared to NHTPR patients. Additionally, the relative abundance of unidentified_Clostridia and Ralstonia was lower in HTPR patients. Significant differences in biological functions, such as toxoplasmosis, were observed between the two groups. The combination of Ralstonia, unidentified-Clostridia, Mailhella, Anaerofustis, and Aggregatibacter showed excellent predictive ability for HTPR occurrence (AUC=0.896). When comparing AIS patients with healthy controls, alterations in the microbiota structure were observed in AIS patients, with imbalances in short-chain fatty acid-producing bacteria and pathogenic bacteria. Significant differences in biological functions, such as oxidative phosphorylation, were noted between the two groups. The combination of Alloprevotella, Terrisporobacter, Streptococcus, Proteus, and unidentified_Bacteria exhibited strong predictive power for AIS occurrence (AUC=0.994).Conclusions: This study is the first to uncover the microbial characteristics of HTPR in AIS patients and demonstrate the predictive potential of specific bacterial combinations for HTPR occurrence.
- 1 December 2022
- Published by ASEAN Neurological Association in Neurology Asia
- Vol. 27 (4) , 835-843
Admission hyperglycemia as an independent predictor of clopidogrel high on-treatment platelet reactivity in ischemic stroke patients
- 1 December 2022
- Published by ASEAN Neurological Association in Neurology Asia
- Vol. 27 (4) , 835-843
Admission hyperglycemia as an independent predictor of clopidogrel high on-treatment platelet reactivity in ischemic stroke patients
- Open Access
- 19 August 2022
- Published by Springer Nature in BMC Neurology
- Vol. 22 (1) , 1-8
The risk factors of neuropathic pain in neuromyelitis optica spectrum disorder: a retrospective case-cohort study
Background: Neuropathic pain is a common complication in neuromyelitis optica spectrum disorder (NMOSD), which seriously affects the quality of life of NMOSD patients, with no satisfactory treatment. And risk factors of neuropathic pain are still uncertain. Objective: To investigate the risk factors of neuropathic pain in a NMOSD cohort. Materials and methods: Our study was a retrospective case-cohort study, the patients diagnosed with NMOSD in the Department of Neurology from the Second Affiliated Hospital of Guangzhou University of Chinese Medicine from January 2011 to October 2021 were screened. Inclusion criteria were: (1) patients diagnosed as NMOSD according to the International Panel for NMO Diagnosis (IPND) criteria, (2) the aquaporin-4 immunoglobulin G antibodies (AQP4-IgG) test was performed. Patients without AQP4-IgG antibody were excluded. Clinical data, including sex, age of the first onset, symptoms of the first episode including neuropathic pain and attack types, localization of lesions of the first episode on Magnetic Resonance Imaging (MRI), Extended disability status Scale (EDSS) of the first onset, treatment of immunosuppression in the first acute phase, disease modifying therapy (DMT), treatment of neuropathic pain and APQ4-IgG status were collected from the hospital system database. Neuropathic pain was defined according to the International Association for the Study of Pain criteria and was described as “pain arising as a direct consequence of a lesion or disease affecting the somatosensory system”. Results: One hundred nineteen patients were screened and finally 86 patients fulfilling the inclusion and exclusion criteria were enrolled in our study. The prevalence of neuropathic pain in patients with NMOSD was 43.0%. Univariate analysis showed that the factors associated with neuropathic pain were the age at the onset, the attack type of optic neuritis, the attack type of myelitis, length of spinal cord involvement, localization of thoracic lesion, optic lesion, upper thoracic lesions, lower thoracic lesions, extended spinal cord lesions (≥ 3 spinal lesions), extended thoracic lesions (≥ 4 thoracic lesions), intravenous immunoglobulin and mycophenolate mofetil. Multivariate regression analysis showed that extended thoracic lesions (OR 20.21 [1.18–346.05], P = 0.038) and age (OR 1.35 (1–1.81) P = 0.050) were independently associated with neuropathic pain among NMOSD patients and that gender (OR 12.11 (0.97–151.64) P = 0.053) might be associated with neuropathic pain among NMOSD patients. Conclusion: Extended thoracic lesions (≥ 4 thoracic lesions), age and gender might be independent risk factors of neuropathic pain among patients with NMOSD. However, with a small sample size and predominantly female, caution must be applied and these results need validating in further cohorts.
- 19 August 2022
- Published by Springer Nature in BMC Neurology
- Vol. 22 (1) , 1-8
Open AccessThe risk factors of neuropathic pain in neuromyelitis optica spectrum disorder: a retrospective case-cohort study
Background: Neuropathic pain is a common complication in neuromyelitis optica spectrum disorder (NMOSD), which seriously affects the quality of life of NMOSD patients, with no satisfactory treatment. And risk factors of neuropathic pain are still uncertain. Objective: To investigate the risk factors of neuropathic pain in a NMOSD cohort. Materials and methods: Our study was a retrospective case-cohort study, the patients diagnosed with NMOSD in the Department of Neurology from the Second Affiliated Hospital of Guangzhou University of Chinese Medicine from January 2011 to October 2021 were screened. Inclusion criteria were: (1) patients diagnosed as NMOSD according to the International Panel for NMO Diagnosis (IPND) criteria, (2) the aquaporin-4 immunoglobulin G antibodies (AQP4-IgG) test was performed. Patients without AQP4-IgG antibody were excluded. Clinical data, including sex, age of the first onset, symptoms of the first episode including neuropathic pain and attack types, localization of lesions of the first episode on Magnetic Resonance Imaging (MRI), Extended disability status Scale (EDSS) of the first onset, treatment of immunosuppression in the first acute phase, disease modifying therapy (DMT), treatment of neuropathic pain and APQ4-IgG status were collected from the hospital system database. Neuropathic pain was defined according to the International Association for the Study of Pain criteria and was described as “pain arising as a direct consequence of a lesion or disease affecting the somatosensory system”. Results: One hundred nineteen patients were screened and finally 86 patients fulfilling the inclusion and exclusion criteria were enrolled in our study. The prevalence of neuropathic pain in patients with NMOSD was 43.0%. Univariate analysis showed that the factors associated with neuropathic pain were the age at the onset, the attack type of optic neuritis, the attack type of myelitis, length of spinal cord involvement, localization of thoracic lesion, optic lesion, upper thoracic lesions, lower thoracic lesions, extended spinal cord lesions (≥ 3 spinal lesions), extended thoracic lesions (≥ 4 thoracic lesions), intravenous immunoglobulin and mycophenolate mofetil. Multivariate regression analysis showed that extended thoracic lesions (OR 20.21 [1.18–346.05], P = 0.038) and age (OR 1.35 (1–1.81) P = 0.050) were independently associated with neuropathic pain among NMOSD patients and that gender (OR 12.11 (0.97–151.64) P = 0.053) might be associated with neuropathic pain among NMOSD patients. Conclusion: Extended thoracic lesions (≥ 4 thoracic lesions), age and gender might be independent risk factors of neuropathic pain among patients with NMOSD. However, with a small sample size and predominantly female, caution must be applied and these results need validating in further cohorts.